Ostabolin inhalation - Nektar Therapeutics/Zelos Therapeutics

Drug Profile

Ostabolin inhalation - Nektar Therapeutics/Zelos Therapeutics

Alternative Names: Cyclic hPTH-(1-31)-NH2 inhalation; Ostabolin-C inhalation; Ostabolin-C inhalation powder; Ostabolin-C pulmonary

Latest Information Update: 13 Oct 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nektar Therapeutics; Zelos Therapeutics Inc
  • Class Osteoporosis therapies; Peptide fragments; Peptide hormones
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Osteoporosis

Most Recent Events

  • 21 Oct 2008 Novartis agrees to acquire certain areas of pulmonary business from Nektar
  • 25 Sep 2007 Clinical data presented at the American Society for Bone and Mineral Research 29th Annual Meeting (ASBMR-2007) added to the adverse events, pharmacokinetics and Musculoskeletal Disorders pharmacodynamics sections ,
  • 21 Sep 2006 Phase-I clinical trials in Osteoporosis in Canada (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top